KalVista reports Q3 net loss $22.5M; KVD900 Phase 3 trial initiated, data expected H2 2023

KalVista Pharmaceuticals, Inc.

Net loss of $22.5M ($0.92/share) vs $10.0M loss ($0.56) YoY; R&D spend $19.7M (up from $9.1M).
Cash and securities $194.8M at Jan 31, 2022, down from $248.9M at Apr 30, 2021.
Initiated Phase 3 KONFIDENT trial for KVD900 on-demand HAE treatment; data expected H2 2023.
Phase 2 KOMPLETE trial for KVD824 (prophylaxis) enrolling on track; data expected mid-2023.
Factor XIIa inhibitor program advancing; first IND anticipated in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.